{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:57:12Z","timestamp":1782561432103,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["NO.81772255"],"award-info":[{"award-number":["NO.81772255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR\/ABL protein, which is encoded by the bcr\/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide application of tyrosine kinase inhibitors (TKIs) in CML treatment, TKIs drug resistance or intolerance limits their further usage in a subset of patients. Furthermore, TKIs inhibit\u00a0the tyrosine kinase activity of the BCR\/ABL oncoprotein while failing to eliminate the pathologenic oncoprotein. To develop alternative strategies for CML treatment using therapeutic antibodies, and to address the issue that antibodies cannot pass through cell membranes, we have established a novel intracellular delivery of anti-BCR\/ABL antibodies, which serves as a prerequisite for CML therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Anti-BCR\/ABL antibodies were encapsulated in poly(<jats:sc>d<\/jats:sc>, <jats:sc>l<\/jats:sc>-lactide-<jats:italic>co<\/jats:italic>-glycolide) nanoparticles (PLGA NPs) by a double emulsion method, and transferrin was labeled on the surface of the nanoparticles (Ab@Tf-Cou6-PLGA NPs). The characteristics of nanoparticles were measured by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Cellular uptake of nanoparticles was measured by flow cytometry (FCM). The effect of nanoparticles on the apoptosis and proliferation of CML cells was testified by FCM and CCK-8 assay. In addition, the anti-cancer impact of nanoparticles was evaluated in mouse models of CML.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results demonstrated that the Ab@Tf-Cou6-PLGA NPs functioned as an intracellular deliverer of antibodies, and exhibited an excellent effect on degrading BCR\/ABL oncoprotein in CML cells via the Trim-Away pathway. Treatment with Ab@Tf-Cou6-PLGA NPs inhibited the proliferation and induced the apoptosis of CML cells in vitro as well as impaired the oncogenesis ability of CML cells in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, our study indicated that this approach achieved safe and efficient intracellular delivery of antibodies and degraded BCR\/ABL oncoprotein via the Trim-Away pathway, which provides a promising therapeutic strategy for CML patients, particularly those with TKI resistance.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-021-01150-x","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:03:19Z","timestamp":1630929799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Intracellular delivery of anti-BCR\/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells"],"prefix":"10.1186","volume":"14","author":[{"given":"Guoyun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"5940","key":"1150_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/306277a0","volume":"306","author":"C Bartram","year":"1983","unstructured":"Bartram C, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith M, Davies T, Stone M. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277\u201380.","journal-title":"Nature"},{"issue":"1","key":"1150_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17(1):49.","journal-title":"Mol Cancer"},{"issue":"4760","key":"1150_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley G, Mes-Masson A, Witte O, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science (New York, NY). 1986;233(4760):212\u20134.","journal-title":"Science (New York, NY)"},{"issue":"3","key":"1150_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1150_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"T Braun","year":"2020","unstructured":"Braun T, Eide C, Druker B. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530\u201342.","journal-title":"Cancer Cell"},{"issue":"3","key":"1150_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2017","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1150_CR7","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"J Apperley","year":"2007","unstructured":"Apperley J. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018\u201329.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"M Zabriskie","year":"2014","unstructured":"Zabriskie M, Eide C, Tantravahi S, Vellore N, Estrada J, Nicolini F, Khoury H, Larson R, Konopleva M, Cortes J, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"issue":"32","key":"1150_CR9","doi-asserted-by":"publisher","first-page":"19221","DOI":"10.1073\/pnas.1919221117","volume":"117","author":"M Hoemberger","year":"2020","unstructured":"Hoemberger M, Pitsawong W, Kern D. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proc Natl Acad Sci USA. 2020;117(32):19221\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41409-019-0513-5","volume":"54","author":"A L\u00fcbking","year":"2019","unstructured":"L\u00fcbking A, Dreimane A, Sandin F, Isaksson C, M\u00e4rkev\u00e4rn B, Brune M, Ljungman P, Lenhoff S, Stenke L, H\u00f6glund M, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019;54(11):1764\u201374.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb H, Lahaye T, Maywald O, Reiter A, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686\u201392.","journal-title":"Blood"},{"issue":"1","key":"1150_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-019-1229-5","volume":"38","author":"Z Luo","year":"2019","unstructured":"Luo Z, Gao M, Huang N, Wang X, Yang Z, Yang H, Huang Z, Feng W. Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells. J Exp Clin Cancer Res. 2019;38(1):224.","journal-title":"J Exp Clin Cancer Res"},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2020.04.010","volume":"482","author":"H Yang","year":"2020","unstructured":"Yang H, Zhou H, Huang Z, Tao K, Huang N, Peng Z, Feng W. Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides. Cancer Lett. 2020;482:44\u201355.","journal-title":"Cancer Lett"},{"issue":"18","key":"1150_CR14","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","volume":"79","author":"G Burslem","year":"2019","unstructured":"Burslem G, Schultz A, Bondeson D, Eide C, Savage Stevens S, Druker B, Crews C. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation. Can Res. 2019;79(18):4744\u201353.","journal-title":"Can Res"},{"issue":"1","key":"1150_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/imr.12234","volume":"263","author":"T Holyoake","year":"2015","unstructured":"Holyoake T, Helgason G. Do we need more drugs for chronic myeloid leukemia? Immunol Rev. 2015;263(1):106\u201323.","journal-title":"Immunol Rev"},{"issue":"1","key":"1150_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R Lu","year":"2020","unstructured":"Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H, Wu H. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.","journal-title":"J Biomed Sci"},{"issue":"6","key":"1150_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","volume":"15","author":"G Weiner","year":"2015","unstructured":"Weiner G. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361\u201370.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1150_CR18","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.cell.2017.10.033","volume":"171","author":"D Clift","year":"2017","unstructured":"Clift D, McEwan W, Labzin L, Konieczny V, Mogessie B, James L, Schuh M. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171(7):1692\u2013706.","journal-title":"Cell"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","volume":"39","author":"V Oke","year":"2012","unstructured":"Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39:77\u201382.","journal-title":"J Autoimmun"},{"issue":"9","key":"1150_CR20","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1093\/emboj\/20.9.2140","volume":"20","author":"A Reymond","year":"2001","unstructured":"Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001;20(9):2140\u201351.","journal-title":"EMBO J"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/bs.aivir.2018.01.002","volume":"100","author":"M Bottermann","year":"2018","unstructured":"Bottermann M, James L. Intracellular antiviral immunity. Adv Virus Res. 2018;100:309\u201354.","journal-title":"Adv Virus Res"},{"issue":"1","key":"1150_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/imr.12363","volume":"268","author":"S Foss","year":"2015","unstructured":"Foss S, Watkinson R, Sandlie I, James L, Andersen J. TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev. 2015;268(1):328\u201339.","journal-title":"Immunol Rev"},{"issue":"12","key":"1150_CR23","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.it.2017.07.005","volume":"38","author":"D Rhodes","year":"2017","unstructured":"Rhodes D, Isenberg D. TRIM21 and the function of antibodies inside cells. Trends Immunol. 2017;38(12):916\u201326.","journal-title":"Trends Immunol"},{"issue":"4","key":"1150_CR24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1021\/acs.bioconjchem.9b00025","volume":"30","author":"K Singh","year":"2019","unstructured":"Singh K, Ejaz W, Dutta K, Thayumanavan S. Antibody delivery for intracellular targets: emergent therapeutic potential. Bioconjug Chem. 2019;30(4):1028\u201341.","journal-title":"Bioconjug Chem"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3389\/fphar.2018.01208","volume":"9","author":"T Slastnikova","year":"2018","unstructured":"Slastnikova T, Ulasov A, Rosenkranz A, Sobolev A. Targeted intracellular delivery of antibodies: the state of the art. Front Pharmacol. 2018;9:1208.","journal-title":"Front Pharmacol"},{"issue":"46","key":"1150_CR26","doi-asserted-by":"publisher","first-page":"e1902791","DOI":"10.1002\/adma.201902791","volume":"31","author":"X Qin","year":"2019","unstructured":"Qin X, Yu C, Wei J, Li L, Zhang C, Wu Q, Liu J, Yao S, Huang W. Rational design of nanocarriers for intracellular protein delivery. Adv Mater (Deerfield Beach Fla). 2019;31(46):e1902791.","journal-title":"Adv Mater (Deerfield Beach Fla)"},{"issue":"10","key":"1150_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/17425247.2017.1273345","volume":"14","author":"F Sousa","year":"2017","unstructured":"Sousa F, Castro P, Fonte P, Kennedy P, Neves-Petersen M, Sarmento B. Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy? Expert Opin Drug Deliv. 2017;14(10):1163\u201376.","journal-title":"Expert Opin Drug Deliv"},{"key":"1150_CR28","unstructured":"Approval Package for Lupron Depot, 4 Months, 30 mg, Leuprolide Acetate https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020517_s002ap.pdf."},{"issue":"4","key":"1150_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12248-021-00611-y","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Qin B, Xia G, Choi S. FDA\u2019s poly(lactic-co-glycolic acid) research program and regulatory outcomes. AAPS J. 2021;23(4):92.","journal-title":"AAPS J"},{"key":"1150_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.phrs.2017.07.011","volume":"126","author":"Z Zhu","year":"2017","unstructured":"Zhu Z, Li Y, Yang X, Pan W, Pan H. The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles. Pharmacol Res. 2017;126:84\u201396.","journal-title":"Pharmacol Res"},{"key":"1150_CR31","doi-asserted-by":"publisher","first-page":"8799","DOI":"10.1021\/acs.analchem.1c00478","volume":"93","author":"J Wu","year":"2021","unstructured":"Wu J, Zhou X, Li P, Lin X, Wang J, Hu Z, Zhang P, Chen D, Cai H, Niessner R, et al. Ultrasensitive and simultaneous SERS detection of multiplex microRNA using fractal gold nanotags for early diagnosis and prognosis of hepatocellular carcinoma. Anal Chem. 2021;93:8799.","journal-title":"Anal Chem"},{"issue":"7","key":"1150_CR32","first-page":"155","volume":"5","author":"M Li","year":"2018","unstructured":"Li M, Sun X, Zhang N, Wang W, Yang Y, Jia H, Liu W. NIR-activated polydopamine-coated carrier-free \u201cnanobomb\u201d for in situ on-demand drug release. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2018;5(7):155.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"5","key":"1150_CR33","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1021\/nn5066793","volume":"9","author":"Q Liu","year":"2015","unstructured":"Liu Q, Chen X, Jia J, Zhang W, Yang T, Wang L, Ma G. pH-Responsive poly(d, l-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response. ACS Nano. 2015;9(5):4925\u201338.","journal-title":"ACS Nano"},{"issue":"6","key":"1150_CR34","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/aps.2017.45","volume":"38","author":"Y Cui","year":"2017","unstructured":"Cui Y, Xu Q, Davoodi P, Wang D, Wang C. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin. Acta Pharmacol Sin. 2017;38(6):943\u201353.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"1150_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.actbio.2011.10.022","volume":"8","author":"F Dilnawaz","year":"2012","unstructured":"Dilnawaz F, Singh A, Sahoo S. Transferrin-conjugated curcumin-loaded superparamagnetic iron oxide nanoparticles induce augmented cellular uptake and apoptosis in K562 cells. Acta Biomater. 2012;8(2):704\u201319.","journal-title":"Acta Biomater"},{"issue":"4","key":"1150_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00232-014-9637-0","volume":"247","author":"S Tortorella","year":"2014","unstructured":"Tortorella S, Karagiannis T. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol. 2014;247(4):291\u2013307.","journal-title":"J Membr Biol"},{"issue":"2","key":"1150_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijpharm.2009.04.035","volume":"379","author":"J Chang","year":"2009","unstructured":"Chang J, Jallouli Y, Kroubi M, Yuan X, Feng W, Kang C, Pu P, Betbeder D. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm. 2009;379(2):285\u201392.","journal-title":"Int J Pharm"},{"issue":"1","key":"1150_CR38","first-page":"22","volume":"38","author":"HL Zhu","year":"2007","unstructured":"Zhu HL, Liu T, Meng WT, Jia YQ. Establishment of an imatinib resistance cell line K562R and its resistant principia. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007;38(1):22\u20136.","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"1150_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1083\/jcb.108.2.389","volume":"108","author":"J Heuser","year":"1989","unstructured":"Heuser J, Anderson R. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J Cell Biol. 1989;108(2):389\u2013400.","journal-title":"J Cell Biol"},{"issue":"2","key":"1150_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijpharm.2015.10.057","volume":"496","author":"M Iqbal","year":"2015","unstructured":"Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent evaporation techniques used for drug encapsulation. Int J Pharm. 2015;496(2):173\u201390.","journal-title":"Int J Pharm"},{"issue":"7","key":"1150_CR41","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1021\/acsnano.5b01320","volume":"9","author":"M Yu","year":"2015","unstructured":"Yu M, Zheng J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano. 2015;9(7):6655\u201374.","journal-title":"ACS Nano"},{"key":"1150_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-8722-3-47","volume":"3","author":"G Wei","year":"2010","unstructured":"Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010;3:47.","journal-title":"J Hematol Oncol"},{"issue":"44","key":"1150_CR43","doi-asserted-by":"publisher","first-page":"22132","DOI":"10.1073\/pnas.1913973116","volume":"116","author":"H Wang","year":"2019","unstructured":"Wang H, Tsourkas A. Cytosolic delivery of inhibitory antibodies with cationic lipids. Proc Natl Acad Sci USA. 2019;116(44):22132\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"99","key":"1150_CR44","doi-asserted-by":"publisher","first-page":"99ra85","DOI":"10.1126\/scitranslmed.3002296","volume":"3","author":"K Guo","year":"2011","unstructured":"Guo K, Li J, Tang J, Tan C, Hong C, Al-Aidaroos A, Varghese L, Huang C, Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med. 2011;3(99):99ra85.","journal-title":"Sci Transl Med"},{"key":"1150_CR45","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","volume":"65","author":"J Markman","year":"2013","unstructured":"Markman J, Rekechenetskiy A, Holler E, Ljubimova J. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65:1866\u201379.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1150_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7150\/thno.20047","volume":"8","author":"J Zhang","year":"2018","unstructured":"Zhang J, Xiong H, Cao J, Wang S, Guo X, Lin B, Zhang Y, Zhao J, Wang Y, Zhang T, et al. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway. Theranostics. 2018;8(2):549\u201362.","journal-title":"Theranostics"},{"key":"1150_CR47","doi-asserted-by":"publisher","first-page":"606518","DOI":"10.3389\/fimmu.2020.606518","volume":"11","author":"T Yamazaki","year":"2020","unstructured":"Yamazaki T, Biswas M, Kosugi K, Nagashima M, Inui M, Tomono S, Takagi H, Ichimonji I, Nagaoka F, Ainai A, et al. A novel gene delivery vector of agonistic anti-radioprotective 105 expressed on cell membranes shows adjuvant effect for DNA immunization against influenza. Front Immunol. 2020;11:606518.","journal-title":"Front Immunol"},{"issue":"5","key":"1150_CR48","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/bit.22858","volume":"107","author":"L Mendon\u00e7a","year":"2010","unstructured":"Mendon\u00e7a L, Moreira J, de Lima M, Sim\u00f5es S. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng. 2010;107(5):884\u201393.","journal-title":"Biotechnol Bioeng"},{"key":"1150_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.032","volume":"111","author":"J Mello","year":"2016","unstructured":"Mello J, Moraes V, Watashi C, da Silva D, Cavalcanti L, Franco M, Yokaichiya F, de Araujo D, Rodrigues T. Enhancement of chlorpromazine antitumor activity by Pluronics F127\/L81 nanostructured system against human multidrug resistant leukemia. Pharmacol Res. 2016;111:102\u201312.","journal-title":"Pharmacol Res"},{"key":"1150_CR50","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ijpharm.2020.119179","volume":"579","author":"L Fan","year":"2020","unstructured":"Fan L, Liu C, Hu A, Liang J, Li F, Xiong Y, Mu C. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches. Int J Pharm. 2020;579:1191.","journal-title":"Int J Pharm"},{"issue":"37","key":"1150_CR51","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M J\u00e4r\u00e5s","year":"2010","unstructured":"J\u00e4r\u00e5s M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum O, Richter J, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107(37):16280\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"1150_CR52","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"R Warfvinge","year":"2017","unstructured":"Warfvinge R, Geironson L, Sommarin M, Lang S, Karlsson C, Roschupkina T, Stenke L, Stentoft J, Olsson-Str\u00f6mberg U, Hjorth-Hansen H, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384\u201394.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01150-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01150-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01150-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T13:10:54Z","timestamp":1630933854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01150-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01150-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and were conducted with the approval of the Ethics Committee of Chongqing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}